Abivax share plunge may change deal outlook

Catch up quick: Abivax, which is dual-listed in Paris, is working on a treatment for bowel disease ulcerative colitis.

• Per CNBC: "The medicine met its endpoints of demonstrating clinically meaningful efficacy and a placebo-adjusted remission rate of about 40% for both doses tested, but also showed that there were cancer cases among patients taking the higher dose."

The bottom line: Some suitors might view this red flag as a buying opportunity, but the likeliest scenario is that everyone waits for a fuller data release in October.